GSK has agreed to pay $55 million upfront and up to $1.005 billion in milestone payments to China’s Suzhou Siran Biotechnology (SiranBio) for exclusive worldwide rights to SA030, a small interfering RNA (siRNA) therapy designed to reduce harmful abdominal fat while preserving lean muscle mass.
The deal, announced on May 5, gives GSK rights to SA030 in all markets outside mainland China, Hong Kong, Macau, and Taiwan, with tiered royalties also due if the drug reaches commercialization.
A Differentiated Approach to Obesity
SA030 targets activin receptor-like kinase 7 (ALK7), a protein linked to visceral fat accumulation, insulin resistance, and inflammatory signaling. Unlike the current generation of GLP-1-based weight-loss drugs, this oligonucleotide therapy aims specifically at cardiometabolic risk driven by abdominal fat rather than overall body weight.
SiranBio said preclinical work has shown a “differentiated, long-acting profile for SA030 that could address the underlying inflammation associated with cardiometabolic risk through adipocyte-directed delivery and a low-frequency dosing schedule”. The drug recently entered phase 1 trials testing tolerability and pharmacokinetics in patients with overweight or obesity.
SiranBio will lead clinical development through phase 1 completion, after which GSK will assume responsibility for further development, regulatory filings, and commercialization in international markets.
GSK’s Growing RNA Pipeline From China
The agreement marks GSK’s second major siRNA licensing deal with a Chinese biotech in recent months. In February, the company paid $40 million upfront to Frontier Biotechnologies for two early-stage siRNA candidates targeting kidney diseases, in a deal also valued at roughly $1 billion including milestones.
Aisar Khavandi, GSK’s senior vice president of research and development, said “SA030 builds on our emerging pipeline targeting inflammation, fibrosis and vascular drivers of disease, and may help improve outcomes for patients”.
Competitive Landscape
The deal places GSK in direct competition with Arrowhead Pharmaceuticals, which is developing its own ALK7-targeting obesity program. GSK’s strategy appears focused on building a cardiometabolic portfolio distinct from the crowded GLP-1 space, betting instead on RNA-based modalities that address the inflammatory and vascular mechanisms underlying metabolic disease.
